In a recent interview with CURE, Dr. Kai Tsao broke down current treatment advancements for patients with prostate cancer.

Epkinly combined with GemOx achieved durable remissions in relapsed/refractory DLBCL, addressing unmet needs in second-line ...

Emphasis on accessible, low-toxicity treatments, including oral therapies, to reduce financial burden and improve patient ...

Treatment with Zervyteg (MaaT013) generated encouraging results and demonstrated an acceptable safety profile in patients with acute graft-vs-host disease that affects the gastrointestinal tract and ...

Orlowski serves as chairman, Ad Interim, and director of Myeloma in the Departments of Lymphoma/Myeloma and Experimental ...

Accurate information about Lynch syndrome is essential. As more people discuss hereditary cancer online, misinformation ...

Among patients experiencing chronic graft-versus-host disease (cGVHD), the transition of treatment with Niktimvo (axatilimab) ...

Dr. Robert Orlowski says a single-drug option in newly diagnosed myeloma may offer strong responses with fewer side effects and preserve future treatments.

Real-time text check-ins helped physicians identify issues sooner and support quality of life for patients with myeloma at ...

OS for Black patients was 57.8 months in those with a favorable ELN cytogenic RS, 14.2 months for those with intermediate RS ...

Among fit patients with acute myeloid leukemia, the combination of azacitidine plus Venclexta (venetoclax) was associated ...

One of biggest stories or developments in acute myeloid leukemia or AML is the wider adoption and use of the regimen of ...